Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbll T, Warren ML, Bain SC
Oba-Yamamoto C, Takeuchi J, Nakamura A, et
CagriSema produced unprecedented mean weight loss of 20.4% at 68 weeks on an intent-to-treat basis, significantly exceeding semaglutide alone (14.9%), cagrilintide alone (11.5%), and placebo (3.0%)
Participants taking oral semaglutide experienced clinically meaningful weight loss, with average reductions exceeding 16% when paired with diet and exercise, and substantial weight loss even without intensive lifestyle modification